** Shares of hormonal disease-focused drug developer Crinetics CRNX.O rise 1.6% to $37.1 in premarket after TD Cowen starts coverage with a "buy" rating
** TD Cowen forecasts sales of $4 billion for co's experimental lead drugs by 2035
** Brokerage says market potential of co's once-daily pill paltusotine could be substantial, given similar drugs from Novartis NOVN.S and Ipsen IPN.PA collectively brought in $2.5 billion of sales in 2023
** Co is testing paltusotine to treat acromegaly, a condition in which excess growth hormone is produced, as well as carcinoid syndrome that causes symptoms from rare tumors
** CRNX is testing another drug, atumelnant, for a rare genetic disorder called congenital adrenal hyperplasia $(CAH)$ and Cushing's syndrome, a hormonal disorder
** "The company's success partly relies on its ability to obtain and maintain patent protection in the US and other countries for its product candidates," brokerage says
** Stock rose 44% in 2024
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。